Achillion Pharmaceuticals Inc., of New Haven, Conn., promoted Milind Deshpande to executive vice president of research.
Acusphere Inc., of Watertown, Mass., named Patrick Gallagher senior vice president of business development.
Alpharma Inc., of Bridgewater, N.J., named Thomas J. Spellman III its executive vice president, chief legal officer and corporate secretary.
Anacor Pharmaceuticals, of Palo Alto, Calif., named Paulette A. Dillon its chief business officer.
Anadys Pharmaceuticals Inc., of San Diego, promoted Carol G. Gallagher to senior vice president of corporate development and commercial affairs.
Anesiva Inc., of South San Francisco, added James A. Harper to its board of directors.
Ariad Pharmaceuticals Inc., of Cambridge, Mass., appointed Pierre F. Dodion to senior vice president, oncology.
Arius Research Inc., of Toronto, named Robert Gundel chief scientific officer.
Avexa Ltd., of Melbourne, Australia, appointed John Sime as a non-executive director of the company.
Avid Radiopharmaceuticals Inc., of Philadelphia, added Ernest Mario to its board of directors.
AxioMed Spine Corp., of Garfield Heights, Ohio, appointed Larry Papasan to its board of directors.
BSP, of Tel Aviv, Israel, has added several members to its scientific advisory board: Anthony N. DeMaria, Ori Ben-Yehuda, George A. Beller, Noel Bairey-Merz, Harold Dauerman, Richard Bach and Gregory Barsness.
Ceapro Inc., of Edmonton, Alberta, appointed Ian W. Cottrell vice president of business development.
Cequent Pharmaceuticals, of Cambridge, Mass., named Johannes Fruehauf director of preclinical and clinical development. Also, Jens Harborth was named associate director, RNAi research.
Champions Biotechnology Inc., of Arlington, Va., appointed Manuel Hidalgo to its board of directors and as a scientific advisor.
ChemGenex Pharmaceuticals, of Menlo Park, Calif., appointed George Morstyn to its board of directors.